“Genus PLC reported a standout first half of fiscal 2026, achieving record profit levels with adjusted profit before tax surging 57% to £55.7 million despite stable revenue. Key drivers included robust growth in the PIC porcine business, particularly from high-margin royalties in China, alongside margin improvements in ABS bovine genetics and a milestone payment from a strategic joint venture. Earnings per share climbed 53% to 60.8 pence, with positive free cash flow of £8.2 million underscoring operational efficiency and strategic execution in pioneering sustainable animal breeding solutions.”
Record Profit and Strategic Growth Initiatives Highlight Genus PLC’s H1 FY2026 Performance
Genus PLC, a global leader in animal genetics, showcased exceptional profitability in the first half of fiscal 2026, ending December 31, 2025. The company posted adjusted profit before tax of £55.7 million, marking a substantial 57% increase year-over-year. This record performance came on the back of unchanged group revenue, highlighting the effectiveness of Genus’s high-margin, royalty-driven business model and disciplined cost management.
The surge in profitability was primarily fueled by the Porcine Improvement Company (PIC) division, which continued its strong momentum. PIC royalty revenue grew 6% to £92.8 million, contributing to an impressive 30% rise in adjusted operating profit to £71.9 million for the segment. This growth was supported by expanded customer adoption of Genus’s advanced genetics, particularly in key markets where demand for efficient, high-health pigs remains elevated despite fluctuating pork prices.
A notable contributor to the results was a £5.6 million milestone payment received from Beijing Capital Agribusiness (BCA), linked to regulatory milestones in the formation and progress of the strategic porcine joint venture in China. This payment, combined with ongoing royalty streams from the region, underscores the long-term value of Genus’s strategic partnerships in one of the world’s largest pork-producing markets.
In the ABS (bovine genetics) division, progress was evident through ongoing value-added product (VAP) initiatives and operational enhancements. These efforts drove margin expansion, helping offset softer market conditions in certain dairy and beef segments. While ABS faced some volume pressures in prior periods, the focus on sexed semen technologies and genomic selection tools continued to yield benefits, positioning the business for sustained profitability gains.
Operationally, Genus generated positive free cash flow of £8.2 million in the half, a meaningful improvement that reflects tighter working capital management and the cash-generative nature of the royalty model. Statutory profit before tax reached £39.5 million, up sharply from £3.3 million in the prior period, while adjusted earnings per share advanced 53% to 60.8 pence.
Management highlighted broad-based strategic progress across the portfolio. In PIC, investments in genetic improvement programs delivered higher-value animals to customers, enhancing farm productivity and sustainability. The China joint venture advanced as planned, with regulatory approvals unlocking further growth potential in royalties and technology transfer.
For ABS, the emphasis remained on innovation in sexed genetics and embryo technologies, which are increasingly adopted to improve herd efficiency and reduce environmental impact in dairy and beef production. These initiatives align with global trends toward more sustainable protein production.
Looking at the balance sheet, net debt levels were managed prudently, supporting flexibility for continued R&D investment and strategic opportunities. The company expressed confidence in entering the second half, noting stable overall market conditions despite persistent disease challenges in some regions and softer pork pricing in China.
The board reiterated expectations for significant adjusted profit before tax growth in full-year 2026, consistent with upgraded market forecasts following the January trading update. Phase III benefits from certain programs are now anticipated at around £7 million for the year, ahead of previous guidance.
Key financial metrics for the first half of FY2026 included:
Group revenue: Stable year-over-year at approximately £335.6 million (down marginally 0.2%)
Adjusted operating profit: Increased notably, driven by PIC strength and ABS improvements
Adjusted profit before tax: £55.7 million (+57%)
Statutory profit before tax: £39.5 million (significant rise)
Adjusted EPS: 60.8 pence (+53%)
Free cash flow: £8.2 million inflow
Dividend: Maintained in line with policy, reflecting confidence in ongoing cash generation
These results demonstrate Genus’s ability to deliver profitable growth through innovation in animal genetics, strategic market positioning, and execution on high-return initiatives. The company’s focus on pioneering solutions for sustainable food production positions it well amid evolving global demands for efficient animal protein.
Disclaimer: This article is for informational purposes only and does not constitute investment advice, financial recommendations, or an offer to buy or sell securities. Investors should conduct their own research and consult professional advisors before making decisions.